Disclaimer: You are now leaving www.HIVReagentProgram.org and are going to a website that is not operated by NIH HIV Reagent Program. We are not responsible for the content or availability of linked sites.
ABOUT THIRD PARTY LINKS ON OUR SITE:
NIH HIV Reagent Program offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links, you will leave the NIH HIV Reagent Program website and will be redirected to another site. These sites are not under the control of NIH HIV Reagent Program.
NIH HIV Reagent Program is not responsible for the content of linked third party websites. We are neither an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.
Please read third party privacy and security policies closely as these may be different than NIH HIV Reagent Program policies.
If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.
Antibody class: IgG1κ
ARP-857 is purified from hybridoma supernatant by protein G affinity chromatography and quantitated by ELISA.
This antibody binds to a discontinuous, or conformational gp120 epitope.
This antibody binds to gp120 on the surface of IIIB, SF2, MN, RF, and CC-infected cells. It neutralizes SF2, IIIB, and MN infection at concentrations ranging from 140 ng/mL to 10 µg/mL.
The hybridoma is generated using human Epstein-Barr Virus-transformed B cells fused with HMMA2.11TG/O heteromyeloma.
Note: The user should determine the optimal concentration for any application.
Each vial of ARP-857 contains 100 µg of purified antibody at a concentration of 1.5 mg/mL, dialyzed against PBS and sterile-filtered. Please refer to the attached file(s) for additional information.
The endotoxin content is 340 EU/mL for lot 160077.
If lower endotoxin is required for your needs, please request Lot No. 150350 in your order. *NOTE: Endotoxin has been shown to induce chemokines and other soluble HIV and SIV inhibitory factors in primary cultures of PBMC, monocytes and macrophages (Verani et al., J. Exp. Med. 185: 805-816, 1997; J. Immunol. 168: 6388-6396, 2002; Montefiori in preparation). Thus, caution is advised when using this reagent for in vitro studies involving primary cells. Immunoreactivity is confirmed by ELISA and purity is assessed by SDS-PAGE analysis.Click Here for Purity and ELISA Data.
Note: Avoid freeze-thaw cycles as reagent degradation may result.
L. A., et al. “Human Monoclonal Antibodies to the V3 Loop of HIV-1 gp120
Mediate Variable and Distinct Effects on Binding and Viral Neutralization by a
Human Monoclonal Antibody to the CD4 Binding Site.” J. Acquir. Immune Defic.
Syndr. 6 (1993): 353-358. PubMed: 8455141.
Posner, M. R., et al. “Neutralization of HIV-1 by F105, a Human Monoclonal
Antibody to the CD4 Binding Site of gp120.”J Acquir. Immune. Defic. Syndr.
6 (1993): 7-14. PubMed: 8417177.
Posner, M. R., H. Elboim, and D. Santos. “The Construction and Use of a Human-Mouse
Myeloma Analogue Suitable for the Routine Production of Hybridomas Secreting
Human Monoclonal Antibodies.” Hybridoma 6 (1987): 611-625. PubMed: 3436625.
Posner, M. R., et al. “An IgG Human Monoclonal Antibody that Reacts with HIV-1/gp120,
Inhibits Virus Binding to Cells, and Neutralizes Infection.” J. Immunol. 146 (1991):
4325-4332. PubMed: 1710248.
When applying for permits and forms please:
Do NOT reference NIH HIV Reagent Program or ATCC Catalog Numbers in the Material Description
fields found on the permits and/or forms.
Make sure your name and address on the permit applications and/or forms are exactly
as they appear on your NIH HIV Reagent Program registration.
Information about permits is provided as a courtesy to NIH HIV Reagent Program customers.
While we use reasonable efforts to include accurate and up-to-date information on
this page, we make no warranties or representation as to its accuracy.
For more information on the necessary compliance requirements associated with the
biological materials provided by NIH HIV Reagent Program, please select this link: Compliance Requirements.
Knowledge Base (FAQs)
Microsoft PowerPoint Viewer
Microsoft Word Viewer
Microsoft Excel Viewer
Call Us Toll-Free:+1 (888) 487-0727
TTY: (703) 365 - 2727